Medico Remedies Ltd
NSE: MEDICO BSE: 540937Pharma
Medico Remedies Ltd (MEDICO) is a Pharma company listed on NSE: MEDICO | BSE: 540937. With a market cap of ₹364 Cr and ROCE of 21.3%, ROE of 17.6%, it operates in the Indian Pharma sector.
₹43.9
52W: ₹30.2 — ₹59
PE 31.4 · Book ₹8.06 · +445% vs bookMarket Cap₹364 Cr
Stock P/E31.4Price to Earnings
ROCE21.3%Return on Capital
ROE17.6%Return on Equity
Div. Yield0%Face Value ₹2
Strengths
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 44.0% CAGR over last 5 years
Weaknesses
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of 11.2% over past five years.
- −Promoter holding has decreased over last 3 years: -12.0%
Shareholding Pattern
Promoters61.38%
FIIs0.03%
DIIs0%
Public38.6%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 73.34% | 73.34% | 66.83%▼6.5 | 63.79%▼3.0 | 62.59%▼1.2 | 61.38%▼1.2 | 61.38% | 61.38% |
| FIIs | 0.22% | 0.22% | 0.39%▲0.2 | 0.11%▼0.3 | 0.07%▼0.0 | 0.3%▲0.2 | 0.49%▲0.2 | 0.03%▼0.5 |
| DIIs | 0.97% | 0.97% | 0.78%▼0.2 | 0.01%▼0.8 | 0.01% | 0.01% | 0%▼0.0 | 0% |
| Public | 25.46% | 25.47%▲0.0 | 32%▲6.5 | 36.08%▲4.1 | 37.33%▲1.3 | 38.3%▲1.0 | 38.13%▼0.2 | 38.6%▲0.5 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.36 | 29.77 | 41.32 | 30.8 | 39.35 | 39.49 | 41.3 | 38.25 | 52.64 | 58.68 |
| Expenses | 39.29 | 27.04 | 36.67 | 27.98 | 36.94 | 36.38 | 34.64 | 35.43 | 49.91 | 54.35 |
| Operating Profit | 3.07 | 2.73 | 4.65 | 2.82 | 2.41 | 3.11 | 6.66 | 2.82 | 2.73 | 4.33 |
| OPM % | 7.25% | 9.17% | 11.25% | 9.16% | 6.12% | 7.88% | 16.13% | 7.37% | 5.19% | 7.38% |
| Net Profit | 2.43 | 1.45 | 3.1 | 1.58 | 1.55 | 2.62 | 4.34 | 1.82 | 2.57 | 2.87 |
| EPS ₹ | 0.29 | 0.17 | 0.37 | 0.19 | 0.19 | 0.32 | 0.52 | 0.22 | 0.31 | 0.35 |
AI Insights
Revenue Trend
TTM revenue at ₹191Cr, up 26.5% YoY. OPM at 9%.
Debt Position
Borrowings at ₹13Cr. Debt-to-equity ratio: 0.26x. Healthy balance sheet.
Institutional Flow
DIIs: 0% (+0.00pp change). FIIs: 0.03% (-1.16pp change). Promoters hold 61.38%.
Margin & Efficiency
ROCE improving from 11% (Mar 2014) to 21% (Mar 2025). Working capital days: 90.
Valuation
PE 31.4x with 21.3% ROCE. Price is 445% above book value of ₹8.06. Dividend yield: 0%.
Recent Announcements
- Board Meeting Intimation for Meeting Of The Board Of The Company To Be Held On Thursday, 21St May 2026, 2d - Board meeting on 21 May 2026 to approve Q4 FY26 and annual audited results.
- Intimation Of Action Taken Or Order Passed By Regulatory, Statutory, Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations') 16 Apr - NSE and BSE levied Rs. 63,720 each for Regulation 6(1) non-compliance; waiver rejected, fines paid.
- Intimation Of Action Taken Or Order Passed By Regulatory, Statutory, Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations') 24 Feb - SoP notices alleging Reg 6(1) breach; penalties Rs63,720 each from NSE and BSE; waiver filed 24-Feb-2026.
- Clarification With Regards To Additional Details Sought In Respect Of Outcome Of Board Meeting Held On 18Th February 2026 Submitted To Exchange On 18Th February 2026 24 Feb - Clarifies board meeting timing and confirms outcome filed within SEBI LODR time on 18 Feb 2026.
- Announcement under Regulation 30 (LODR)-Change in Management 18 Feb - Board appointed Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer on 18 Feb 2026.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse